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Abstract
Background: The human Sushi Domain-Containing Protein 4 (SUSD4) was recently shown to function as a novel
inhibitor of the complement system, but its role in tumor progression is unknown.
Methods: Using immunohistochemistry and quantitative PCR, we investigated SUSD4 expression in breast cancer tissue
samples from two cohorts. The effect of SUSD4 expression on cell migration and invasion was studied in vitro using two
human breast cancer cell lines overexpressing SUSD4.
Results: Tissue stainings revealed that both tumor cells and tumor-infiltrating cells expressed SUSD4. The highest SUSD4
expression was detected in differentiated tumors with decreased rate of metastasis, and SUSD4 expression was associated
with improved survival of the patients. Moreover, forced SUSD4 expression in human breast cancer cells attenuated their
migratory and invasive traits in culture. SUSD4 expression also inhibited colony formation of human breast cancer cells
cultured on carcinoma-associated fibroblasts. Furthermore, large numbers of SUSD4-expressing T cells in the tumor
stroma associated with better overall survival of the breast cancer patients.
Conclusion: Our findings indicate that SUSD4 expression in both breast cancer cells and T cells infiltrating the
tumor-associated stroma is useful to predict better prognosis of breast cancer patients.
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Background
Sushi Domain-Containing Protein 4 (SUSD4), described
so far in only two scientific papers, is a poorly studied
human protein. The protein is predicted to be expressed
as two different isoforms, where one is membrane-bound
(SUSD4a) and the other soluble (SUSD4b). SUSD4a is a
49 kDa protein composed of four CCP (complement con-
trol protein) domains, a transmembrane region, and a
cytoplasmic tail. SUSD4b is a smaller isoform (27 kDa)
consisting of three CCP domains and a region of unknown
homology. The protein may be further N-glycosylated at
three predicted sites. Both isoforms are quite broadly
expressed on mRNA level in many human tissues. We
have previously demonstrated that SUSD4 functions as a
complement inhibitor [1] but other possible functions of
this protein remain unclear. In our previous study, we de-
tected SUSD4 positive tumor-infiltrating cells in colon,
lung and breast cancer, suggesting that SUSD4 might play
a role in cancer progression.
It is unclear if complement and its regulators are bene-
ficial or detrimental for the progression of cancer. As of
yet, no clear consensus has been reached and the litera-
ture shows evidence of both hypotheses [2]. Comple-
ment can kill certain types of cancer cells. Because of
this, cancer cells protect themselves against complement
attack by expressing soluble or membrane-bound com-
plement inhibitors [3, 4]. This is true for the widely
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expressed membrane-bound complement inhibitors, for
example CD46 and CD59. On the other hand, comple-
ment activation can aid cancer progression by the
production of C5a [5] and the creation of a chronic in-
flammatory environment. This means that complement
can be beneficial or detrimental to cancer development,
or perhaps both depending on the circumstances. Most
likely, the outcome of complement activation on cells
will highly depend on the environment and will differ
for solid versus blood tumors. Therefore we now aimed
to assess the expression of the complement inhibitor
SUSD4 in human breast cancer and to determine if the
degree of expression may be related to clinical prognosis.
Here, we show that SUSD4 is expressed by epithelial
tumor cells, in which it affects migration and invasion,
and in tumor-infiltrating CD8+ and CD4+ T cells. Fur-
thermore, expression of SUSD4 is associated with an im-
proved prognosis for breast cancer patients.
Methods
Immunohistochemical staining of breast cancer tissue
microarrays (TMAs)
Tissue samples obtained from a cohort of 144 women
diagnosed with breast cancer in Skåne, Sweden [6] were
stained with rabbit anti-SUSD4 (home-made) as previ-
ously validated and described [1]. Ethical permission
was obtained from the Lund University Regional Ethics
Board, ref. no. 445/2007 whereby written consent was
not required and patients were offered the option to
opt out. The intensity of the SUSD4-specific signal in
tumor cells was scored 0 (no expression), 1 (low ex-
pression) or 2 (high expression) independently by two
scientists and one experienced clinical pathologist, who
were all blinded with regard to clinical information. For
statistical analyses, the scores were grouped into SUSD4
negative (score 0) and SUSD4 positive tumors (scores
1–2). In the stroma of the tumors, SUSD4 positive
tumor-infiltrating cells were detected. The cells were
counted for the whole tissue section and grouped into
0–15 (low) or 16–100 (high) SUSD4+ cells/section.
Kaplan-Meier analyses and Breslow tests were used to
determine the effect of SUSD4 expression by tumor
cells or infiltrating cells on cancer-specific survival and
recurrence-free survival. Uni- and multivariable Cox
proportional hazard models based on SUSD4 expres-
sion were used to determine hazard ratios (HR) for
cancer-specific death. Immunohistochemical data re-
garding hormone receptor status, Ki-67 and human
epidermal growth factor receptor 2 (HER2) expression
were available from previous studies [6, 7]. Definitions
of estrogen receptor (ER) and progesterone receptor
(PR) negativity followed current Swedish clinical guide-
lines (<10 % positive nuclei). Ki-67 status was assessed
based on the percentage of positively stained nuclei and
dichotomized into ≤25 % and >25 %. HER2 status was
assessed by semiquantitative analysis according to a
standard protocol [8]. Specimens were grouped as
weakly (scores 0–2) and strongly expressing HER2
(score 3). Any differences in the distribution of clinical
parameters and SUSD4 expression were calculated for
tumor cells and tumor-infiltrating cells by using 2-tailed
Mann–Whitney U tests. Exact p-values <0.05 were con-
sidered statistically significant. The calculations were per-
formed using SPSS Statistics v. 22 (IBM). The original
slides were scanned with an Aperio ScanScope slide scan-
ner and representative pictures (40X magnification) were
obtained in the ImageScope software (Aperio).
SUSD4 RNA transcript analysis in a breast cancer cohort
Fresh frozen mammary tissues (normal, n = 32 and
tumour, n = 127) from patients with breast cancer were
collected immediately after surgery, under the research
ethics approval from the Southeast Wales Research Eth-
ics Committee and with informed consent, and stored at
−80 °C until used. Patients were followed up routinely in
the clinics with a median follow-up at 120 months, and
their clinical characterisation was published previously
[9]. The tissues were homogenized and total RNA was
purified. cDNA was synthesized from 1 μg RNA ac-
cording to the manufacturer’s specifications (AbGene).
A qPCR was set up as described in [9], using the fol-
lowing primers for SUSD4: 5’-AAAACCTTATCTGGT
CGTC-3’ and 5’-ACTGAACCTGACCGTACATCTCC
GTGACTCACCATT-3’. A standard of cytokeratin-19
(CK19) was run simultaneously using primers 5’-CAG
GTCCGAGGTTACTGAC-3’ and 5’-ACTGAACCTGA
CCGTACACACTTTCTGCCAGTGTGTCTTC-3’. The
standard was used to obtain the transcript levels. The
data were analyzed by Kaplan-Meier followed by Breslows
test to determine if SUSD4 transcript levels affected
cancer-specific survival or recurrence free survival. SUSD4
transcript levels were correlated to clinical parameters
using Mann–Whitney U tests.
Cells
Breast cancer cell lines MDA-MB-231 and BT20
(American Type Culture Collection, ATCC) were cul-
tured in DMEM high glucose (Thermo Scientific)
medium supplemented with 10 % fetal bovine serum
(FBS), penicillin and streptomycin. Cells were frozen
immediately after re-cultivation of the original aliquot,
and all the experiments were performed on cultures
originating from these secondary aliquots within no
more than 5 passages. Cells were Mycoplasma nega-
tive and tested monthly for contamination with the
VenorGEM Classic kit (Minerva Biolabs). Although
SUSD4 is predicted to be expressed as two isoforms,
we focused this study only on the cancer-related
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functions of the membrane-bound SUSD4a, which is the
isoform easily detectable at protein level. Full-length
SUSD4a [1] was cloned into the pcDNA3 vector (Life
technologies) using restriction sites EcoRI and XhoI. The
construct or empty vector (mock) were transfected to
MDA-MB-231 and BT20 cells using lipofectamine 2000
(Life technologies) and clones were selected with G418
(Life technologies). Cell pellets were collected and RNA
was purified with the RNeasy kit (Qiagen). cDNA was syn-
thesized from 1 μg RNA by using 2.5 μM oligo(dT) pri-
mer, 24 U RnaseOUT, and 200 U Superscript III reverse
transcriptase (Life technologies). A qPCR was set up using
10 ng cDNA/well in triplicate for each sample. Specific
primers detecting SUSD4a (Hs01042141_m1), cyclophilin
A (Hs99999904_m1), TATA-box binding protein (Hs00427
621_m1), and hypoxanthine phosphoribosyltransferase 1
(HPRT-1; Hs99999909_m1) were bought from Applied
Biosystems. SUSD4a expression relative to the geometrical
mean of the three references was calculated according to
the ΔCt method [10].
SUSD4a protein expression was analysed by flow cy-
tometry and western blot. For flow cytometry, 200 000
cells/well were incubated with 5 μg/ml anti-SUSD4 di-
luted in binding buffer (10 mM HEPES, 140 mM NaCl,
5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 0.02 % w/v
NaN3, pH 7.2) for 1 hour at RT. The cells were washed in
binding buffer, incubated with a secondary antibody con-
jugated to fluorescein isothiocyanate (FITC) for 30 min at
RT, then resuspended in binding buffer and analysed by
flow cytometry (Partec CyFlow Space flow cytometer) and
the FlowJo software. For the western blot, lysates were run
on a 12 % SDS-PAGE under reducing conditions. The gel
was blotted (Trans-Blot Turbo, Bio-Rad) to a PVDF mem-
brane, stained with 0.1 μg/ml anti-SUSD4 followed by a
secondary antibody conjugated to horseradish peroxidase
(HRP) and developed with ECL (Millipore).
Growth assay
Cells (6000 cells/well) were plated out in duplicates
in four identical 96-well plates (Nunc). The plates
were incubated for 0.5 h, 24 h, 72 h, or 96 h, before
cell fixation with 4 % formaldehyde and staining with
0.5 % w/v crystal violet. Excess dye was washed away
with tap water and the plate was left to dry over
night. The dye was extracted with 10 % acetic acid
and the absorbance was read at 540 nm using a mi-
croplate reader (Cary50Bio, Varian). The data were
normalized to the highest value of each repetition.
Adhesion
A layer of matrigel (5 μg/well, BD Biosciences) was
coated in quadruplicates in a 96-well plate. After drying
and rehydration of the matrigel, cells (MDA-MB-231;
3x104 cells/well and BT20; 5x104 cells/well) were
allowed to bind for 45 min at 37 °C. Unbound cells were
removed by washing with BSS (680 mM NaCl, 15 mM
KCl, 7 mM KH2PO4, 3.5 mM Na2HPO4, pH 7.2). The
cells were fixed with 4 % formaldehyde and stained with
0.5 % w/v crystal violet as described above. After the
plate was dry, two random pictures were taken of each
well (40X objective; EVOS FL inverted microscope) and
the cells were counted (ImageJ).
Wound healing assay
Cells were grown to confluency in a 6-well plate (Nunc).
Two scratches were made per well with a sharpened
yellow pipette tip. Pictures were taken at three posi-
tions (exactly the same position every time using a
10X objective) along each scratch at 0 h, 3 h and 6 h.
The wound area was measured in ImageJ and the average
of the 6 positions was used. The data were normalized to
the wound area at 0 h for each sample.
Migration and invasion
Cells were resuspended in DMEM high glucose medium
supplemented with 1 % FBS and placed in plain inserts
(migration, 8 microns, BD Biosciences) in duplicates or
inserts coated with matrigel (invasion, 8 microns, BioCoat,
Corning) in singlet. The inserts were placed (before the
addition of cells) in wells containing DMEM high glucose
supplemented with 10 % FBS. Cells (MDA-MB-231; 5x104
cells/well and BT20; 10x104 cells/well) were left to mi-
grate/invade for 22 h (MDA-MB-231) or 44 h (BT20).
Cells that had moved to the underside of the inserts were
fixed with formaldehyde and stained with crystal violet.
Four pictures were taken of each inserts using a 40X ob-
jective and the number of migrating/invading cells was
quantified with ImageJ.
Clonogenic co-culture assay
Carcinoma-associated fibroblasts (CAFs) or control ori-
ginating from breast tissue [11] were cultured O/N in
triplicates in a 96-well plate (5x103 cells/well). SUSD4a-
or mock-transfected BT20 cells (100 cells/well) were
added to each well and were cultured for 10 days. The
cells were fixed with 70 % ethanol and stained with
0.1 % w/v toluidine blue (Sigma-Aldrich). Excess dye
was removed with BSS and the plate was left to dry O/N.
A picture of each well was taken using a 4X objective
and the average cluster size of the colonies was quan-
tified with ImageJ. Additional representative pictures
were taken using a 40X objective.
Adhesion of cancer cells to CAFs
CAFs were grown to confluency in quadruplicates in a
96-well plate before the addition of SUSD4a- or mock-
transfected MDA-MB-231 or BT20 cells (30x103 cells/
well). The plate was incubated for 45 min and unbound
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cells were removed with BSS. Adherent cells were fixed
with formaldehyde and stained with toluidine blue. The
plate was rinsed with tap water and allowed to dry O/N
at RT. Two random pictures were taken of each well
using a 40X objective and the number of adherent can-
cer cells was counted using ImageJ.
Fluorescence microscopy
Breast cancer TMAs (as described above) were double-
stained for SUSD4 (2 μg/ml) and CD3 (10 μg/ml; clone
OKT3; eBioscience), CD4 (8 μg/ml; clone 4B12; Dako)
or CD8 (3 μg/ml; clone C8/144B; Dako) as described
previously [12]. Pictures were taken with a Zeiss LCM
510 confocal microscope (20X objective).
Purification of T cells
Peripheral blood was drawn from healthy volunteers ac-
cording to the permit of the local ethical committee in
Lund, Sweden. Peripheral blood mononuclear cells
(PBMCs) were isolated by centrifugation over a density
gradient (Lymphoprep, Stemcell technologies). CD4+ or
CD8+ T cells were purified from the PBMCs by using
specific kits (Miltenyi Biotec). Wells (48-well plate) were
coated O/N at 4 °C with a mix of 2 μg/ml anti-CD3 and
2 μg/ml anti-CD28 (clone CD28.2; eBioscience) diluted
in PBS. The isolated T cells were either immediately fro-
zen at −80 °C (fresh) or stimulated for 24 h in coated
wells in RPMI medium (Thermo Scientific) supple-
mented with 10 % FBS and 5 U/ml IL-2 (Immunotools).
Fresh and stimulated T cells were used for SUSD4a ex-
pression analysis simultaneously by both qPCR and
western blot. The experiment was performed three times
using blood from different donors.
RNA was purified (RNeasy, Qiagen) and cDNA was
synthesized as described above. SUSD4a gene expression
was analysed by qPCR using 10 ng cDNA/well as de-
scribed above. Three different primers specific for
SUSD4a (Hs01042141_m1, Hs01047294_m1, Hs010472
93_m1), and the reference primers (Applied Biosystems)
cyclophilin A, beta-2 microglobulin (B2M, Hs009842
30_m1), and HPRT-1 were used.
The fresh or stimulated T cells were lysed in RIPA buf-
fer and 10 μg total protein/sample was analysed by 12 %
SDS-PAGE under reducing conditions. The gel was blot-
ted and the membrane was stained as described above.
After development of the SUSD4a signal, the lower part
of the blot was washed and stained for the loading con-
trol B2M (17 ng/ml; Abcam, ab75853).
Results
SUSD4 expression is associated with better survival at
both protein and RNA levels
The intensity of the SUSD4 staining in tumor cells
was scored 0, 1 or 2 (Fig. 1a) and the number of
SUSD4+ infiltrating cells in each section was counted
(Fig. 1b). Kaplan-Meier analyses and Breslow tests
showed that SUSD4 expression in tumor cells and in
the tumor infiltrating cells had a positive effect on
the breast cancer specific survival rate of the patients
(Fig. 1c, e), but did not significantly affect recurrence
free survival (Fig. 1d, f ).
Associations between SUSD4 expression in tumor
cells and clinical parameters showed that SUSD4+
tumors had a tendency (p = 0.066) to be smaller
(Table 1). The SUSD4+ tumors were more differenti-
ated (NHG; p < 0.001), and less prone to lymph node
metastasis (nodal status; p = 0.027) as compared to
SUSD4− tumors.
Cox uni- and multivariable analyses were performed
in order to determine the prognostic value of SUSD4
expression in tumor cells (Table 2). The results indi-
cated that SUSD4 was an independent biomarker for
cancer-specific survival (p = 0.040; HR: 0.34; 95 % CI:
0.1 – 0.9).
A higher number of SUSD4+ infiltrating cells in the
tumor stroma were associated with a diagnosis at an
earlier age (p = 0.006). It was also associated with
more differentiated (NHG; p = 0.045) and ER positive
(p = 0.041) tumors (Table 1). The SUSD4 expression
in infiltrating cells was significantly associated with
survival in the univariable Cox analysis (p = 0.039;
HR: 0.12; 95 % CI: 0.02 – 0.9), but not in the multi-
variable test (p = 0.192; HR: 0.25; 95 % CI: 0.03 – 2.0,
Table 2) indicating that it was not an independent
predictor of survival.
RNA was purified from breast cancer tissues iso-
lated from patients included in a second independent
cohort, and SUSD4 transcript levels were analysed by
qPCR. Kaplan-Meier analyses showed that the pres-
ence of SUSD4 transcripts in the tumor tissues was
significantly associated with improved cancer specific
survival (p = 0.009; Fig. 1g), but not recurrence free
survival (p = 0.220; Fig. 1h). The Nottingham Prognos-
tic Index (NPI) tended to be lower for tumors with
higher levels of SUSD4 transcripts (p = 0.054), which
indicated that 85 % of patients with SUSD4-
expressing tumors survived for at least 5 years (NPI
score ≤3.4; compared to score ≥5.4 which represented
a 5 year survival rate of 50 %). Tumors expressing
high levels of SUSD4 transcripts tended to be less in-
vasive (p = 0.056; negative vs. positive nodal status).
SUSD4a affects the long-term growth of cancer cells
The breast cancer cell lines MDA-MB-231 and BT20
were stably transfected with SUSD4a cDNA or empty
vector (mock). The RNA expression was verified by
qPCR using a specific primer (Fig. 2a, d). Protein
expression was tested by flow cytometry (Fig. 2b, e) and
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Fig. 1 (See legend on next page.)
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by western blot (Fig. 2c, f ). All three experiments veri-
fied the expression of SUSD4a in both cell lines.
No statistically significant differences were observed
when comparing the growth rate of SUSD4a- or mock-
transfected MDA-MB-231 cells (Fig. 3a). For BT20 cells,
there were no differences after 24 hours but after 72 and
96 hours a significantly decreased growth rate was ob-
served for cells expressing SUSD4a (Fig. 3f).
(See figure on previous page.)
Fig. 1 SUSD4 expression in breast cancer is associated with an improved prognosis. A cohort of breast cancer tissue samples were stained for SUSD4, and
the intensity of the staining in tumor cells was scored 0, 1, or 2. Representative pictures were taken at 40X magnification (a). The scores were grouped into
SUSD4+ (1, 2) or SUSD4− (0) tumors. The number of SUSD4+ infiltrating cells was counted in each section, and was grouped into low (0–15 cells/section)
and high (16–100 cells/section). Representative pictures are shown in b. Kaplan-Meier analyses showed that SUSD4 expression by tumor cells was associated
with prolonged breast cancer specific survival of the patients (c), but recurrence free survival was not affected (d). A higher number of SUSD4+ infiltrating
cells in the stroma was also beneficial for the survival rate (e), while it did not affect recurrence free survival (f). SUSD4 transcript levels were analysed by qPCR
in a second cohort of breast cancer samples. Increased levels of SUSD4 transcripts was associated with improved survival (g), but not with recurrence free
survival (h).
Table 1 Associations between SUSD4 and clinical parameters
Factor Patient SUSD4+ tumor cells Patient SUSD4+ infiltrating cells
No Yes P* 0-15 16-100 P*
N N
All 123 46 (37) 77 (63) 123 87 (71) 36 (29)
Age at diagnosis 123 0.047 123 0.006
Median (min, max) 63 (34, 97) 67 (35, 91) 68 (34, 97) 61 (41, 79)
Tumor size, 123 0.066 123
Median mm (min, max) 23.5 (10, 73) 21 (7, 145) 23 (8, 145) 19.5 (8, 73) 0.143
NHG <0.001 0.045
I N (%) 15 2 (13) 13 (87) 17 11 (65) 6 (35)
II 58 16 (28) 42 (72) 56 35 (63) 21 (37)
III 50 28 (56) 22 (44) 50 41 (82) 9 (18)
Nodal status 0.027 0.853
0 N (%) 58 16 (28) 42 (72) 60 42 (70) 18 (30)
1-3 34 14 (41) 20 (59) 32 23 (72) 9 (28)
>4 18 10 (56) 8 (44) 18 13 (72) 5 (28)
Missing 13 13
ER status 0.008 0.041
Negative N (%) 18 12 (67) 6 (33) 17 16 (94) 1 (6)
Positive 105 34 (32) 71 (68) 106 71 (67) 35 (33)
PR status 0.117 0.295
Negative N (%) 40 19 (48) 21 (52) 40 31 (78) 9 (22)
Positive 83 27 (32) 56 (68) 83 56 (68) 27 (32)
HER2 0.013 1.000
Negative N (%) 112 38 (34) 74 (66) 106 77 (73) 29 (27)
Positive 9 7 (78) 2 (22) 11 8 (73) 3 (27)
Missing 2 6
Ki67 0.239 0.136
0-24 % N (%) 50 17 (34) 33 (66) 52 34 (65) 18 (35)
>25 % 58 27 (47) 31 (53) 57 45 (79) 12 (21)
Missing 15 14
*Mann–Whitney, 2-tailed Exact p-value
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SUSD4a is not involved in adhesion
To determine if SUSD4 alters the adhesive properties of
the cancer cells, adhesion to matrigel was tested. The re-
sults showed no significant differences between the
SUSD4- and mock-transfected cells (Fig. 3b, g).
Expression of SUSD4a slows migration and invasion of
cancer cells
Both the wound healing assay and the migration assay
were used to test if SUSD4 influences cell motility. In
the wound healing assay, cell movement was random
and a significant difference between SUSD4a- and mock-
transfected BT20 cells was observed after 3 hours (Fig. 3h),
but not for the MDA-MB-231 cell line (Fig. 3c). In the mi-
gration assay, where the cells migrated towards higher
serum concentrations, both MDA-MB-231 and BT20 cells
transfected with SUSD4a moved significantly slower as
compared to the mock (Fig. 3d, i).
The invasion assay tests both migration along a
serum gradient and the ability of the cells to digest
through a layer of extracellular matrix (Matrigel). A
decreased ability to invade was observed for both cell
lines expressing SUSD4 as compared to mock-transfected
cells (Fig. 3e, j).
Cancer cells expressing SUSD4a form smaller colonies
when co-cultured with CAFs
The ability of BT20 cells to form colonies on a mono-
layer of fibroblasts was assessed in a clonogenic assay.
BT20 cells expressing SUSD4a formed significantly
smaller colonies when in co-culture with CAFs (Fig. 4a),
but not with control fibroblasts (Fig. 4b). The MDA-
MB-231 cell line did not form colonies when co-
cultured with CAFs or control fibroblasts. The smaller
size of the colonies was not due to decreased adhesion
of the SUSD4a expressing cancer cells to CAFs, as was
shown for both MDA-MB-231 (Fig. 4c) and BT20 cells
(Fig. 4d).
SUSD4 is expressed by tumor-infiltrating T cells
In order to determine which type of stromal infiltrating
cells expressed SUSD4, fluorescent double-stainings
were performed on the human breast cancer sections.
Stainings with anti-SUSD4 and anti-CD3 (Fig. 5a) re-
vealed that these cells are T cells. Further stainings with
anti-CD4 (Fig. 5b) or anti-CD8 (Fig. 5c), showed that
both CD4+ and CD8+ T cells expressed SUSD4.
SUSD4 expression by CD4+ and CD8+ T cells isolated from
peripheral blood
SUSD4 expression in T cells purified from peripheral
blood was evaluated by qPCR and western blot. The
qPCR and the western blot were performed on T cells
isolated at the same time and each repetition represents
one donor. SUSD4a gene expression was very similar for
all three tested primers, and the results showed that
SUSD4a mRNA expression was downregulated upon T
cell stimulation (Fig. 6a, one representative primer is
shown). However, SUSD4a protein was more than 2.5-
fold upregulated in the stimulated T cells (Fig. 6b). These
data suggest changes in regulation of SUSD4a expression
during T cell activation and therefore a potential involve-
ment of SUSD4a in T cell function.
Table 2 Cox uni- and multivariate analyses of associations between SUSD4 expression and known predictive markers for survival.
Survival tumor cells Univariate Multivariate
Variable N HR 95 % CI P N HR 95 % CI P
SUSD4 (no vs. yes) 122 0.41 0.2-0.9 0.042 107 0.34 0.1-0.9 0.040
Age at diagnosis 144 1.05 1.0-1.1 0.003 107 1.05 1.0-1.1 0.008
ER (neg vs. pos) 144 0.23 0.1-0.5 0.001 107 0.40 0.1-1.1 0.090
NHG 144 5.14 2.0-13.0 0.001 107 1.60 0.4-5.8 0.478
Size (<20 vs. >20 mm) 144 3.04 1.2-7.8 0.020 107 2.37 0.6-9.1 0.209
Ki67 (weak vs. strong) 124 4.26 1.4-12.8 0.010 107 1.65 0.4-6.6 0.483
Survival infil. cells Univariate Multivariate
Variable N HR 95 % CI P N HR 95 % CI P
SUSD4 (low vs. high) 122 0.12 0.02-0.9 0.039 108 0.25 0.03-2.0 0.192
Age at diagnosis 144 1.05 1.0-1.1 0.003 108 1.03 1.0-1.06 0.125
ER (neg vs. pos) 144 0.23 0.1-0.5 0.001 108 0.56 0.2-1.7 0.318
NHG 144 5.14 2.0-13.0 0.001 108 2.14 0.6-7.8 0.250
Size (<20 vs. >20 mm) 144 3.04 1.2-7.8 0.020 108 2.18 0.6-8.6 0.265
Ki67 (weak vs. strong) 124 4.26 1.4-12.8 0.010 108 1.20 0.3-5.6 0.815
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Discussion
SUSD4 is not a well-studied protein and there are only
two published papers [1, 13] pertaining to the function
of the protein. Here, we show that breast cancer epithe-
lial cells express SUSD4 and that positive expression was
significantly associated with a prolonged patient survival.
This may be explained, at least in part, by our observa-
tion that SUSD4a affects cell migration, invasion and
clonogenic ability. Furthermore, expression of SUSD4 on
infiltrating T cells was identified and as expected, in-
creased numbers of such cells was correlated with in-
creased patient survival.
We have previously shown that both isoforms of
SUSD4, a and b, produced as tagged recombinant pro-
teins, inhibit complement by affecting the C3 conver-
tase [1]. In addition, we detected SUSD4 expression on
tumor infiltrating cells in several types of cancer. In this
study, we aimed to identify the role of SUSD4 in breast
cancer. For the in vitro assays, we transfected either
SUSD4a or SUSD4b cDNA into the MDA-MB-231 and
BT20 cell lines, and both cell lines showed high expres-
sion levels of SUSD4a or SUSD4b mRNA. When per-
forming functional assays on these cells, both SUSD4
isoforms had very similar effect. However, we have not
been able to detect the SUSD4b protein either in cell
lysate or in conditioned medium. The specificity of our
affinity purified polyclonal anti-SUSD4 antibody had
already been validated [1]. The antibody was raised
against the CCP domains common for both SUSD4 iso-
forms, and therefore it was not possible to distinguish
between the isoforms in the tissue stainings. However,
western blotting allowed us to determine the particular
Fig. 2 Expression of SUSD4 in two breast cancer cell lines. SUSD4a was overexpressed in the MDA-MB-231 and BT20 cell lines. The expression
was verified at RNA level by qPCR (a, d), and at protein level by flow cytometry (b, e) and western blot of cell lysates (c, f). The data in the Fig.
represents three independent repetitions ± SD (a, d), representative histograms (b, e) and blots (c, f)
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Fig. 3 SUSD4 is involved in cell migration and invasion. To determine the role of SUSD4 in breast cancer, several functional assays were preformed.
The growth assay showed no difference between SUSD4a- and mock- transfected MDA-MB-231 (a), while the SUSD4a-transfected BT20
cells grew slower after 72 hours (f). The ability of cancer cells to adhere to matrigel was not affected by SUSD4a (b, g), but the protein
could influence migration. Random migration was decreased in BT20 cells expressing SUSD4a after 3 hours (h), but not in MDA-MB-231
cells (c). SUSD4a decreased both directed migration (d, i), along a gradient of serum, and invasion through a layer of matrigel (e, j) in
both tested cell lines. The data represents at least three independent experiments ± SD. SUSD4a was compared to mock by 2-way ANOVA
with Bonferroni post-test (a, c, f, h), or unpaired Student’s t-test (b, d, e, g, i, j). The symbols ns, *, **, and *** stand for not significant,
p < 0.05, p < 0.01, and p < 0.001
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SUSD4 isoform based on the different molecular
weight of the proteins. It is possible that the impaired
detection of wild type SUSD4b is caused by a differ-
ent folding of the protein devoid of the tag, or there
is an additional regulation downstream of transcrip-
tion. Nonetheless, since we could not detect expres-
sion of untagged SUSD4b protein, we opted not to
show in vitro results pertaining to SUSD4b and only
discuss the effects of SUSD4a.
In vitro functional studies revealed that SUSD4 expres-
sion decreased the growth rate of BT20 cells after
72 hours, but the growth rate of MDA-MB-231 was not
affected. SUSD4 expression also decreased the migration
and invasion of both cell lines. The effect of SUSD4
Fig. 4 SUSD4a expressing BT20 cells form smaller colonies. The clonogenic potential of BT20 cells expressing SUSD4a was tested in
co-culture with fibroblasts. SUSD4a-transfected BT20 cells formed significantly smaller colonies in co-culture with CAFs (a) but not with
control fibroblasts (b). The ability of the SUSD4a-transfected cells to adhere to CAFs was also tested. No significant differences were
observed for either MDA-MB-231 (c) or BT20 (d). The graphs represent data collected from at least three independent experiments ± SD;
ns and ** stand for not significant and p < 0.01, respectively
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expression was more pronounced for BT20 cells. It is
important to note that SUSD4 did not affect the cell
cycle of the tested cell lines (data not shown). Taken to-
gether, these data suggest that SUSD4 independently in-
hibits both growth and migration of cancer cells. The
decreased invasiveness of the cells was likely due to de-
creased migration. Co-cultures of BT20 cells with CAFs,
but not with control fibroblasts, showed formation of
smaller colonies of cells expressing SUSD4 as compared
to mock. This assay primarily measured cell proliferation
of the cancer cells, but since we only observed an effect
of SUSD4 in co-culture with CAFs and not control fi-
broblasts, this cannot be the only important factor. Pos-
sibly, the CAFs secrete factors affecting the cancer cells
and thereby enhance the anti-tumor effects of SUSD4.
In this study, we showed that SUSD4 expression in
tumor cells and tumor-infiltrating cells was associated
with higher survival rates of breast cancer patients. The
SUSD4-expressing tumor-infiltrating cells were identi-
fied as CD4+ and CD8+ T cells. Although it is known
that the presence of infiltrating T cells is beneficial for
breast cancer-specific survival [14, 15], it has not been
Fig. 5 SUSD4 is expressed by tumor-infiltrating T cells. In order to determine what type of infiltrating cells express SUSD4, fluorescent double
stainings were preformed. Staining with anti-SUSD4 and anti-CD3 showed that SUSD4+ infiltrating cells are T cells (a). Both CD4+ (b) and CD8+
(c) T cells are positive for SUSD4
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shown that these cells express SUSD4, which is here
identified as a protein suppressing the aggressive pheno-
type of breast cancer cells. SUSD4 mRNA expression in
total peripheral blood CD4+ and CD8+ T cells was down-
regulated during stimulation, while SUSD4a protein ex-
pression was upregulated. This suggests a negative
regulation of SUSD4a mRNA during T cell activation,
which is not necessarily contradictory to increases in
protein levels, if combined with decreases in post-
transcriptional regulation of expression or protein turn-
over. The increased level of SUSD4a protein in activated
T cells provides further explanations for the finding that
levels of SUSD4+ infiltrating cells are associated with in-
creased survival, as an active anti-tumor T-cell response
would be beneficial to patients. It is of note that another
complement receptor, CD46, which also consists of 4 CCP
domains, functions as a strong co-stimulatory receptor on
human T cells [16]. The function and factors controlling
expression of SUSD4 on T cells therefore demand further
investigation.
The knowledge about the role of complement in
human diseases, including cancer, is still expanding. For
a long time complement was believed to support the
host against tumor cells, but new studies also show a
pro-tumor activity of certain complement components
[17]. Based on our present study it is hard to determine
whether the tumor-suppressing effect of SUSD4 stems
from the complement function of this protein or
whether it is another, independent function. SUSD4 is
not the first complement inhibitor implied to regulate
tumor growth. The putative tumor suppressor CSMD1
was already shown to diminish complement activation at
the level of C3b [18]. On the other hand, the expression
of complement inhibitors by tumor cells has also been
associated with enhanced tumor progression manifested
by larger tumor size, lower differentiation rate, shorter
survival time and shorter remission [19, 20].
Interestingly, another CCP domain-containing pro-
tein has also been identified to suppress the pheno-
type of tumors. SUSD2 expression by HeLa cells was
shown to inhibit cell migration and invasion [21], al-
though the SUSD2 and SUSD4 genes are located to
different chromosomes (22q11 and 1q41, respectively).
Additionally, SUSD2 contains only one CCP domains and
is thus unlikely to inhibit complement, since such activity
usually requires at least three consecutive CCP domains.
Conclusion
In summary, SUSD4 expression by tumor cells improved
the survival rate of breast cancer patients and led to de-
creased growth rate and migration of transfected cells in
vitro. Furthermore, SUSD4 is expressed by CD4+ and
CD8+ T cells in tumor stroma, which correlates with
good prognosis. Although SUSD4 has previously been
described as a novel complement inhibitor, it is likely
that the protein’s anti-tumor effects are independent of
its complement-related functions.
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